These findings suggest that inhibition of STAT3 signaling contributes to the anti-CRC effects of AR, and support the notion that targeting STAT3 is a strategy for developing novel anti-CRC targeted therapies. This evidence concerns the gene STAT3 and colorectal carcinoma.